Therapeutic Area | MeSH |
---|---|
cardiovascular diseases | D002318 |
nutritional and metabolic diseases | D009750 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ZOCOR | Organon | N-019766 RX | 1991-12-23 | 4 products, RLD |
FLOLIPID | TCG Fluent Pharma | N-206679 RX | 2016-04-21 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
JUVISYNC | Merck & Co | N-202343 DISCN | 2011-10-07 | 6 products, RLD |
Brand Name | Status | Last Update |
---|---|---|
ezetimibe and simvastatin | ANDA | 2025-05-02 |
flolipid | New Drug Application | 2023-02-09 |
simcor | New Drug Application | 2010-08-06 |
simvastatin | ANDA | 2025-05-20 |
simvastatin simvastatin | ANDA | 2022-08-22 |
vytorin | New Drug Application | 2024-11-20 |
zocor | New Drug Application | 2025-03-28 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Prostatic neoplasms | D011471 | — | C61 | 1 | 3 | — | — | 2 | 6 |
Multiple myeloma | D009101 | — | C90.0 | 2 | 4 | — | — | 1 | 6 |
Plasma cell neoplasms | D054219 | — | — | 2 | 4 | — | — | 1 | 6 |
Lung neoplasms | D008175 | — | C34.90 | — | 5 | — | — | — | 5 |
Small cell lung carcinoma | D055752 | — | — | — | 4 | — | — | — | 4 |
Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 2 | 3 | — | — | — | 4 |
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 2 | — | — | — | 3 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | 2 | — | — | 1 | 3 |
Cardiomyopathies | D009202 | EFO_0000318 | I42 | — | 2 | — | — | 1 | 3 |
Cystic fibrosis | D003550 | EFO_0000390 | E84 | 2 | 1 | — | — | 1 | 3 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hiv infections | D015658 | EFO_0000764 | B20 | 3 | — | — | — | — | 3 |
Acute kidney injury | D058186 | — | N17 | 1 | — | — | — | 2 | 3 |
Pulpitis | D011671 | EFO_1001139 | K04.0 | 1 | — | — | — | 2 | 3 |
Hemangioma | D006391 | — | D18.0 | 2 | — | — | — | — | 2 |
Stomatognathic diseases | D009057 | — | K08.9 | 2 | — | — | — | — | 2 |
Dental pulp diseases | D003788 | EFO_0009540 | K04 | 2 | — | — | — | — | 2 |
Lymphoma | D008223 | — | C85.9 | 1 | — | — | — | — | 1 |
Neurotoxicity syndromes | D020258 | — | G92 | 1 | — | — | — | — | 1 |
Lipodystrophy | D008060 | — | E88.1 | 1 | — | — | — | — | 1 |
Hiv seronegativity | D018023 | — | — | 1 | — | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Congenital heart defects | D006330 | — | Q24.9 | — | — | — | — | 2 | 2 |
Heart valve diseases | D006349 | EFO_0009551 | I08 | — | — | — | — | 2 | 2 |
Aneurysm | D000783 | — | I72.9 | — | — | — | — | 2 | 2 |
Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 2 | 2 |
Cerebrovascular disorders | D002561 | EFO_0003763 | I60-I69 | — | — | — | — | 1 | 1 |
Endocrine system diseases | D004700 | EFO_0001379 | E34.9 | — | — | — | — | 1 | 1 |
Chest pain | D002637 | — | R07.9 | — | — | — | — | 1 | 1 |
Stents | D015607 | — | — | — | — | — | — | 1 | 1 |
Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | — | 1 | 1 |
Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | — | — | — | 1 | 1 |
Drug common name | Simvastatin |
INN | simvastatin |
Description | Simvastatin is a member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug. It has a role as an EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor, a prodrug, an EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor, a ferroptosis inducer and a geroprotector. It is a delta-lactone, a fatty acid ester, a statin (semi-synthetic) and a member of hexahydronaphthalenes. It is functionally related to a lovastatin. |
Classification | Small molecule |
Drug class | enzyme inhibitors: antihyperlipidemics (HMG-CoA inhibitors) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CCC(C)(C)C(=O)O[C@H]1C[C@@H](C)C=C2C=C[C@H](C)[C@H](CC[C@@H]3C[C@@H](O)CC(=O)O3)[C@H]21 |
PDB | — |
CAS-ID | 79902-63-9 |
RxCUI | — |
ChEMBL ID | CHEMBL1064 |
ChEBI ID | 9150 |
PubChem CID | 54454 |
DrugBank | DB00641 |
UNII ID | AGG2FN16EV (ChemIDplus, GSRS) |